DeepMed Research

ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients

Phase 2

Completed

Conditions: Induction of Labor Affected Fetus / Newborn

Interventions: Drug: Placebo
Drug: Propranolol

First Posted Date: 2017-11-21

Last Posted Date: 2020-01-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 240

Registration Number: NCT03348683

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps

Phase 2

Completed

Conditions: Head and Neck Cancer
Free Tissue Transfer

Interventions: Drug: Ropivicaine
Drug: Local Saline Infusion

First Posted Date: 2017-11-21

Last Posted Date: 2020-11-17

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 24

Registration Number: NCT03349034

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Anxiety About Casual Exposure to Food Allergens

Not Applicable

Completed

Conditions: Food Allergy

Interventions: Behavioral: Education
Behavioral: Behavioral intervention group

First Posted Date: 2017-11-21

Last Posted Date: 2019-02-21

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT03349047

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma
GBM

Interventions: Drug: Avelumab
Combination Product: MRI-guided LITT therapy

First Posted Date: 2017-11-14

Last Posted Date: 2022-01-04

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 13

Registration Number: NCT03341806

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Phase 2

Terminated

Conditions: Locally Advanced Breast Cancer

Interventions: Drug: Docetaxel
Drug: Pertuzumab
Drug: Carboplatin
Drug: Trastuzumab
Drug: Doxorubicin
Drug: Pegfilgrastim
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2017-11-06

Last Posted Date: 2023-08-22

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 7

Registration Number: NCT03329378

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸
Mount Sinai West, New York, New York, United States

Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?

Phase 4

Completed

Conditions: Knee Rheumatism
Knee Osteoarthritis

Interventions: Drug: Obturator nerve regional block
Drug: Saline
Drug: Adductor canal regional block

First Posted Date: 2017-10-31

Last Posted Date: 2020-09-30

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 60

Registration Number: NCT03326999

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL

Phase 1

Completed

Conditions: Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-10-10

Last Posted Date: 2023-02-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 6

Registration Number: NCT03305445

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1

Active, not recruiting

Conditions: Breast Neoplasms
Breast Diseases

Interventions: Drug: Anastrozole
Drug: Palbociclib
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2017-10-06

Last Posted Date: 2024-08-01

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 44

Registration Number: NCT03304080

Locations: 🇺🇸
Perlmutter Cancer Center NYU Langone, New York, New York, United States
🇺🇸
New York Presbyterian Weill Cornell Medical Center, New York, New York, United States
🇺🇸
New York Presbyterian Columbia Irving Comprehensive Cancer Center, New York, New York, United States

and more 2 locations

Assessing Pyridium for Post-Sling Urinary Retention

Phase 4

Completed

Conditions: Urinary Retention

Interventions: Drug: Phenazopyridine

First Posted Date: 2017-10-05

Last Posted Date: 2019-10-29

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 98

Registration Number: NCT03302936

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting

Phase 4

Completed

Conditions: Post-operative Nausea and Vomiting

Interventions: Drug: Ondansetron 4 MG
Drug: Ondansetron 8mg

First Posted Date: 2017-09-29

Last Posted Date: 2020-07-20

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 141

Registration Number: NCT03297021

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy